Homologous, Heterologous COVID-19 Boosters Are Immunogenic

MONDAY, Feb. 7, 2022 (HealthDay News) -- For adults who completed a primary COVID-19 vaccine regimen at least 12 weeks earlier, homologous and heterologous booster vaccines are immunogenic, according to a study published online Jan. 26 in the New England Journal of Medicine.
Robert L. Atmar, M.D., from the Baylor College of Medicine in Houston, and colleagues conducted a phase 1-2, open-label clinical trial at 10 U.S. sites involving 458 adults who had completed a COVID-19 vaccine regimen at least 12 weeks earlier, had no reported history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and received a booster dose with mRNA-1273, Ad26.COV2.S, or BNT162b2 (154, 150, and 153 participants, respectively; one participant did not receive the assigned vaccine).
The researchers found that reactogenicity was similar to that of the primary series. Injection-site pain, malaise, headache, or myalgia were reported by more than half the recipients. Antibody neutralizing titers against a SARS-CoV-2 D614G pseudovirus increased by a factor of 4 to 73 for all combinations; binding titers increased by a factor of 5 to 55. Neutralizing antibody titers increased by a factor of 4 to 20 with homologous boosters and by a factor of 6 to 73 with heterologous boosters. In all but the homologous Ad26.COV2.S-boosted subgroup, spike-specific T-cell responses increased. In the Ad26.COV2.S-primed recipients, CD8+ T-cell levels were more durable; spike-specific CD8+ T cells were increased substantially with heterologous boosting with the Ad26.COV2.S vaccine in mRNA vaccine-primed individuals.
"These data suggest that an immune response will be generated for each of these vaccines used as a booster regardless of the primary COVID-19 vaccination regimen," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry, including Pfizer, Moderna, and Johnson & Johnson.
Related Posts
Is the Pandemic Affecting Newborns’ Brains?
TUESDAY, Jan. 4, 2022 (HealthDay News) -- Babies born at the height of the...
Pocos jóvenes reciben un fármaco para la adicción, aunque suben las muertes por opioides en los adolescentes
MARTES, 24 de enero de 2023 (HealthDay News) -- El número de adolescentes...
Resilience May Improve Health of Older Adults with T2DM
THURSDAY, Oct. 13, 2022 (HealthDay News) -- Psychological resilience is...
Teen Patients Have Positive Long-Term Outcomes After Bariatric Surgery
TUESDAY, Oct. 11, 2022 (HealthDay News) -- Significant and sustained reductions...